A single center evaluation of cost savings related to treatment-free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco-economy larger study

Br J Haematol. 2020 May;189(3):e97-e100. doi: 10.1111/bjh.16511. Epub 2020 Feb 10.

Authors

Gabriel Etienne^{1

2

3}, Stéphanie Dulucq⁴, Carole Faberes¹, Fontanet Bijou¹, Anna Schmitt¹, Emilie Klein⁴, Marie-Pierre Fort¹, Françoise Durrieu¹, Emilie Toulza¹, François-Xavier Mahon^{1

2

3}

Affiliations

¹ Département d'Hématologie, Institut Bergonié, Bordeaux, France.
² Laboratory of Mammary and Leukaemic Oncogenesis, INSERM U1218, Université de Bordeaux, Bordeaux, France.
³ Groupe Fi-LMC, Hôpital Haut-Lévêque, Pessac, France.
⁴ Laboratoire d'Hématologie, Hôpital Haut Lévêque CHU de Bordeaux, Pessac, France.

PMID: 32043283
DOI: 10.1111/bjh.16511

No abstract available

Keywords: cost savings; treatment-free remission; tyrosine kinase inhibitors.

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Cost Savings / methods*
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / economics*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Male
Middle Aged
Remission Induction / methods*